TL;DR
This study investigated the safety and potential cardiovascular benefits of tofacitinib, a Janus kinase (JAK) inhibitor, in patients with mild-to-moderate systemic lupus erythematosus (SLE). The trial found tofacitinib to be safe and well-tolerated, and importantly, it improved key cardiometabolic and vascular markers associated with the increased cardiovascular risk seen in SLE patients.
What Problem Does This Paper Address?
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a significantly increased risk of premature cardiovascular disease (CVD), even in younger individuals. This heightened risk is not fully explained by traditional CVD risk factors and is thought to be linked to chronic inflammation, immune dysregulation, and specific pathways like the type I interferon (IFN) system and neutrophil activity. Existing treatments have not effectively addressed this accelerated atherosclerosis. This paper explores whether tofacitinib, a JAK inhibitor known to modulate inflammatory pathways, could offer a therapeutic benefit by improving these cardiovascular risk factors in SLE patients.
Methods
This was a Phase 1, double-blind, randomized, placebo-controlled safety trial. Thirty SLE subjects with mild-to-moderate disease activity were randomized in a 2:1 ratio to receive either tofacitinib (5 mg twice daily) or a placebo for 8 weeks, followed by a 4-week follow-up period. The primary outcome was safety and tolerability. Secondary outcomes included clinical response and mechanistic studies, focusing on cardiometabolic parameters, immune markers, and vascular function.
Key techniques employed included:
- Phosphoflow cytometry: To assess the phosphorylation of STAT proteins (STAT1, STAT3, STAT5), indicating JAK pathway activity.
- Whole blood RNA sequencing (RNA-seq) and Nanostring: To analyze gene expression, specifically focusing on the type I IFN gene signature.
- Flow cytometry: To quantify low-density granulocytes (LDGs).
- ELISA and other assays: To measure levels of circulating neutrophil extracellular traps (NETs), high-density lipoprotein (HDL) cholesterol and particle number, lecithin: cholesterol acyltransferase (LCAT) concentration, and cholesterol efflux capacity.
- Non-invasive vascular function studies: Including cardioankle vascular index (CAVI), pulse wave velocity (PWV), and reactive hyperemia index (RHI) to assess arterial stiffness and endothelial function.
- Statistical analysis: Using mixed-effects models and ANCOVA to compare changes from baseline between treatment groups, with stratification by STAT4 risk allele status.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- JAK inhibition as a potential CVD intervention in SLE: The study provides early evidence that targeting the JAK-STAT pathway with tofacitinib may not only address SLE-related immune dysregulation but also directly improve cardiovascular risk factors.
- STAT4 risk allele as a potential biomarker: The findings suggest that individuals with the STAT4 risk allele, known to be associated with more severe SLE and increased CVD risk, may experience more robust benefits from tofacitinib, particularly in terms of NET reduction and improvements in HDL function and arterial stiffness. This opens avenues for personalized medicine approaches.
- Modulation of the IFN-neutrophil axis: Tofacitinib effectively reduced the type I IFN gene signature and modulated specific neutrophil populations (LDGs) and NET formation, which are implicated in SLE-associated vascular damage.
- Impact on HDL metabolism: The drug significantly improved HDL cholesterol levels, particle number, and LCAT activity, suggesting a positive impact on reverse cholesterol transport, a key process in preventing atherosclerosis.
Key Results
- Safety: Tofacitinib was found to be safe and well-tolerated in mild-to-moderate SLE patients, with no severe adverse events, opportunistic infections, or thromboembolic events reported.
- Cardiometabolic improvements:
- Significant increase in HDL-C levels (p = 0.0006, 95% CI: 4.12, 13.32).
- Significant increase in HDL particle number (p = 0.0008, 95% CI: 1.58, 5.33).
- Significant increase in LCAT concentration (p = 0.024, 95% CI: 1.1, -26.5).
- A trend towards improved cholesterol efflux capacity (p = 0.08, 95% CI: -0.01, 0.24).
- Vascular function improvements:
- Improvements in arterial stiffness (CAVI, PWV) and endothelium-dependent vasorelaxation (RHI).
- These improvements were more pronounced in subjects with the STAT4 risk allele.
- Immunologic changes:
- Significant decrease in the type I IFN gene signature.
- Significant decrease in low-density granulocytes (LDGs).
- Significant decrease in circulating NETs, particularly in STAT4 risk allele-positive subjects.
- Inhibition of pSTAT1 in CD4+ T cells.
Limitations and Future Work
- Small sample size and short duration: The study enrolled only 30 subjects for a relatively short treatment period (8 weeks). This limits the statistical power to detect smaller effects and assess long-term efficacy or safety.
- Exploratory nature: The study was a Phase 1 trial, and adjustments for multiple comparisons were not made, meaning some findings should be interpreted cautiously.
- Mild-to-moderate disease: The results may not be generalizable to patients with more severe SLE.
- No concomitant immunosuppressants: The safety profile in patients on other immunosuppressive therapies remains unknown.
Future work should focus on larger, longer-term trials to confirm these findings, assess the efficacy of tofacitinib in preventing CVD events in SLE, and further explore the role of the STAT4 risk allele in predicting treatment response. Investigating the precise mechanisms by which tofacitinib modulates neutrophil function and vascular parameters is also warranted.
Summary updated